The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple
sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with …

Multiple sclerosis (MS) is a chronic disease of the central nervous system with a global
prevalence of more than 2 million cases worldwide 1 and nearly one million cases in the US …

Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter
lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective …

Importance Biomarkers distinguishing nonrelapsing progressive disease biology from
relapsing biology in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an …

Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …

Myasthenia gravis (MG) is an autoimmune disorder that affects the neuromuscular junction,
leading to muscle weakness and fatigue. MG is caused by antibodies against the …

Multiple sclerosis is an inflammatory and degenerative disease characterized by different
clinical courses including relapsing multiple sclerosis (RMS) and primary progressive …

Infusion of T cells engineered to express chimeric antigen receptors (CARs) that target B
cells has proven to be a successful treatment for B cell malignancies. This success inspired …

Currently, there are four monoclonal antibodies (mAbs) that target the cluster of
differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab …

This review addresses current changes in the approach to treating patients with multiple
sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment …